Iovance Biotherapeutics Inc

IOVA

NASDAQ. Currency in USD

6.92 -0.25 ( -3.49% )

Real time prices: December 09

Market Cap.
1.09B
Beta (5Y monthly)
0.38
Price/Earnings
-
EPS (TTM)
-2.47
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
16.00M
1y Target Est.
24.85
Day's Range
6.41
-
6.96
52 Week's Range
5.42
-
20.60

Historical Summary

Performance
EPS growth
Share Buybacks

About Iovance Biotherapeutics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.iovance.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
156.90M
Employees
319
Address
825 Industrial Road, San Carlos, CA, United States, 94070
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Latest news

What 6 Analyst Ratings Have To Say About Iovance Biotherapeutics
What 6 Analyst Ratings Have To Say About Iovance Biotherapeutics

Within the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings: Bullish Somewhat...
By Benzinga - 6 hours ago

US Stocks Start Week On Lower Note; Dow Tumbles 250 Points
US Stocks Start Week On Lower Note; Dow Tumbles 250 Points

U.S. stocks traded lower this morning, with the Dow Jones falling around 250 points on...
By Benzinga - 4 days ago

$65 Million Bet On Iovance Biotherapeutics? Check Out These 3 Stocks Insiders Are Buying
$65 Million Bet On Iovance Biotherapeutics? Check Out These 3 Stocks Insiders Are Buying

Although US stocks closed mixed on Friday, there were a few notable insider trades. When...
By Benzinga - 4 days ago

Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug
Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug

Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA...
By Zacks Investment Research - 2 weeks ago

NIO To Surge Around 105%? Plus Keybanc Predicts $165 For This Stock
NIO To Surge Around 105%? Plus Keybanc Predicts $165 For This Stock

Keybanc raised the price target on AMETEK, Inc. (NYSE: AME) from $145 to $165. Keybanc...
By Benzinga - 2 weeks ago

What 4 Analyst Ratings Have To Say About Iovance Biotherapeutics
What 4 Analyst Ratings Have To Say About Iovance Biotherapeutics

Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings within the last quarter: Bullish Somewhat...
By Benzinga - 2 weeks ago

Why Iovance Biotherapeutics Is Crashing Today
Why Iovance Biotherapeutics Is Crashing Today

The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte...
By The Motley Fool - 3 weeks ago